Updated Jul 16, 2026
Doraiswamy Vinayak has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $381K.
Vinayak Doraiswamy is the Chief Scientific Officer at AtriCure, Inc., a company specializing in surgical treatments for atrial fibrillation and related conditions. He has been involved in the company's efforts to innovate in cardiac ablation and left atrial appendage management.
| Role | Chief Scientific Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | ATRC | AtriCure, Inc. | A — Grant or award | 636 | $23.78 | $15K |
| 2026-05-18 | ATRC | AtriCure, Inc. | S — Open-market sale | 5.0K | $28.13 | $141K |
| 2026-03-16 | ATRC | AtriCure, Inc. | S — Open-market sale | 5.0K | $29.83 | $149K |
| 2026-03-03 | ATRC | AtriCure, Inc. | F — Tax withholding / forfeiture | 15.6K | $31.26 | $487K |
| 2026-03-03 | ATRC | AtriCure, Inc. | A — Grant or award | 15.2K | $0.00 | |
| 2026-03-03 | ATRC | AtriCure, Inc. | A — Grant or award | 30.4K | $0.00 | |
| 2025-08-05 | ATRC | AtriCure, Inc. | S — Open-market sale | 2.5K | $36.58 | $91K |
| 2025-06-30 | ATRC | AtriCure, Inc. | A — Grant or award | 822 | $25.84 | $21K |
Vinayak Doraiswamy is the Chief Scientific Officer at AtriCure, Inc., a company specializing in surgical treatments for atrial fibrillation and related conditions. He has been involved in the company's efforts to innovate in cardiac ablation and left atrial appendage management.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($381K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Doraiswamy Vinayak profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.